These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3297633)

  • 1. [Prolactin, depression and antidepressive agents. Review of the literature].
    Ben Hadj Ali B
    Encephale; 1987; 13(3):101-12. PubMed ID: 3297633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central serotonergic changes following antidepressant treatment: a neuroendocrine assessment.
    Leatherman ME; Ekstrom RD; Corrigan M; Carson SW; Mason G; Golden RN
    Psychopharmacol Bull; 1993; 29(2):149-54. PubMed ID: 8290659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Different effects of tricyclic (clomipramine and amitriptyline) and tetracyclic (maprotiline) antidepressors on the release of thyroid stimulating hormone, prolactin and growth hormone to thyrostimulating releasing hormone in patients with psychoaffective disorders (author's transl)].
    Schlienger JL; Kapfer MT; Singer L; Stephan F
    Acta Psychiatr Belg; 1980; 80(5):584-99. PubMed ID: 6786002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The biochemistry of depression. A survey of monoaminergic, neuroendocrinological, and bio-rhythmic disturbances in endogenous depression.
    Lingjaerde O
    Acta Psychiatr Scand Suppl; 1983; 302():36-51. PubMed ID: 6132523
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of antidepressant treatment on thyrotropin-releasing hormone stimulation, growth hormone response to L-DOPA, and dexamethasone suppression tests in major depressive patients.
    Esel E; Kartalci S; Tutus A; Turan T; Sofuoglu S
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):303-9. PubMed ID: 14751427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical response to antidepressant treatment and 3-methoxy-4-hydroxyphenylglycol levels: mini review.
    Yoshimura R; Nakamura J; Shinkai K; Ueda N
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jul; 28(4):611-6. PubMed ID: 15276685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and biochemical aspects of depressive disorders: III. Treatment and controversies.
    Caldecott-Hazard S; Schneider LS
    Synapse; 1992 Feb; 10(2):141-68. PubMed ID: 1585257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation strategies for treatment-resistant depression.
    Ros S; Agüera L; de la Gándara J; Rojo JE; de Pedro JM
    Acta Psychiatr Scand Suppl; 2005; (428):14-24, 36. PubMed ID: 16307616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A silver bullet for the treatment of depression?
    Duman RS
    Neuron; 2007 Sep; 55(5):679-81. PubMed ID: 17785173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine, depression and antidepressants.
    Dailly E; Chenu F; Renard CE; Bourin M
    Fundam Clin Pharmacol; 2004 Dec; 18(6):601-7. PubMed ID: 15548230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5HT1A receptors and pharmacotherapy. Is serotonin receptor down-regulation linked to the mechanism of action of antidepressant drugs?
    Stahl S
    Psychopharmacol Bull; 1994; 30(1):39-43. PubMed ID: 7972628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Thyrotropin-releasing hormone in psychiatry: marker, predictor and therapeutical tool].
    Babinski T; Paunović VR
    Srp Arh Celok Lek; 1994; 122(11-12):341-3. PubMed ID: 17974414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of postnatal isolation rearing and antidepressant treatment on the density of serotonergic and noradrenergic axons and depressive behavior in rats.
    Kuramochi M; Nakamura S
    Neuroscience; 2009 Sep; 163(1):448-55. PubMed ID: 19524023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invivo antioxidant status: a putative target of antidepressant action.
    Zafir A; Ara A; Banu N
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):220-8. PubMed ID: 19059298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New approaches to antidepressant drug discovery: beyond monoamines.
    Berton O; Nestler EJ
    Nat Rev Neurosci; 2006 Feb; 7(2):137-51. PubMed ID: 16429123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Research progress on therapeutic mechanism of depression treated by traditional chinese medicine].
    Mao QQ; Huang Z
    Zhongguo Zhong Yao Za Zhi; 2007 May; 32(10):877-80. PubMed ID: 17655134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic properties of serotonergic agents and antidepressant drugs.
    Fuller RW
    J Clin Psychiatry; 1987 Mar; 48 Suppl():5-11. PubMed ID: 3493240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lithium augmentation in treatment-resistant depression: clinical evidence, serotonergic and endocrine mechanisms.
    Bschor T; Lewitzka U; Sasse J; Adli M; Köberle U; Bauer M
    Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S230-4. PubMed ID: 14677084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The serotonin transporter and depression.
    Owens MJ; Nemeroff CB
    Depress Anxiety; 1998; 8 Suppl 1():5-12. PubMed ID: 9809208
    [No Abstract]   [Full Text] [Related]  

  • 20. Regulation of neurotransmitter receptors by desipramine and other antidepressant drugs: the neurotransmitter receptor hypothesis of antidepressant action.
    Stahl SM
    J Clin Psychiatry; 1984 Oct; 45(10 Pt 2):37-45. PubMed ID: 6090439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.